SUMMARY A prospective, randomised, double blind, matched cohort survey using retrospective data was undertaken to assess the long term incidence of osteonecrosis of the hip and adverse medical effects occurring after intravenous pulsed methylprednisolone used in the treatment of rheumatoid arthritis over the period 1977-86. One hundred and forty three patients were matched for age, sex, duration and severity of the disease, erosive and serological status. Information was obtained by direct questioning and from hip x rays, the latter being read independently by two 'blind' radiologists. Two definite cases of osteonecrosis were identified, one in both the treated and control groups and three possible cases (radiological disagreement) in the treated group. Adverse medical events, when analysed by systems, were similar in both groups. This study did not provide evidence of increased osteonecrosis of the hip or adverse medical events in the treated group compared with the control group.
For many years intravenous methylprednisolone (IVMP) has been employed with benefit as a therapeutic agent in renal transplantation and for over a decade in connective tissue diseases such as systemic lupus erythematosus and more recently rheumatoid arthritis (RA). [1] [2] [3] [4] [5] [6] [7] [8] [9] The adverse effects of IVMP occurring at the time of administration or within a few days are well documented. These include sudden death102 and death due to infections,'3 14 hypersensitivity,'5 and a variety of complications varying in incidence and sevety. 1619
This variety of effects almost certainly reflects the severity and type of disease being treated, the dose regimen, and degree of monitoring. Although osteonecrosis is recognised as a late complication following renal transplantation, it is uncertain whether the incidence is higher with IVMP than with an oral glucocorticoid preparation.2022 There Accepted for publication 18 March 1988. Correspondence to Dr I A Williams, Department of Rheumatology, Kent and Sussex Hospital, Tunbridge Wells, Kent TN4 8AT. is no definite information about the long term incidence of osteonecrosis or adverse medical effects after the use of IVMP in RA.
To assess these effects we undertook a prospective, randomised, double blind, matched cohort survey using retrospective data obtained from the records of all patients with RA who had been treated in one rheumatology department. Over one fifth of these patients had been treated with IVMP within the previous eight to nine years Tables  2 and 3 show the distribution of IVMP infusions. 
Of the 143 patients treated with IVMP, five had died, eight were uncontactable, and thus 130 interviewed. Tables 4 and 5 show the results of the questionnaire relating to deterioration of hips, radiological assessments, and adverse medical events.
The mean duration in months from the first IV-MP infusion to the most recent hip x ray was 56.3 months (range 8-116), only two patients being x rayed within 12 months of their initial infusion. All 21 Haajanen et al, who routinely x rayed 546 renal transplant recipients, noted a similar incidence but found there was a significant correlation with the number of IV-MP pulses which tended to be given in multiple infusions over relatively short periods,22 a regimen differing from that used in RA.
In this study there was one radiologically agreed The 'study power' is curtailed, however, by the number of patients available, but as the authors are not aware of a larger cohort of patients with RA treated with IVMP over a similar period this probably represents the upper limit of precision currently obtainable. The study, nevertheless, excludes a 'gross effect' by IVMP on the hips of patients with RA. Table 6 shows the clinical status of the two patients with definite and the three with doubtful osteonecrosis.
Although the recording of concomitant drug treatment for all patients was considered impractical, the case notes of those with definite or doubtful osteonecrosis were studied to establish whether they had received corticosteroids. Two of the 'doubtful' group had received a short course of an oral preparation during the study period, but none had received an intra-articular injection into their hips. It is noteworthy that the control patient with definite osteonecrosis had not received any form of corticosteroid.
It is interesting that only five of the treated patients died compared with 11 
